Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women

Stan L. Block, Terry Nolan, Carlos Sattler, Eliav Barr, Katherine E.D. Giacoletti, Colin D. Marchant, Xavier Castellsagué, Steven A. Rusche, Suzanne Lukac, Janine T. Bryan, Paul F. Cavanaugh, Keith S. Reisinger and ; for the Protocol 016 Study Group
Pediatrics November 2006, 118 (5) 2135-2145; DOI: https://doi.org/10.1542/peds.2006-0461
Stan L. Block
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terry Nolan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Sattler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliav Barr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine E.D. Giacoletti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin D. Marchant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Castellsagué
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Rusche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne Lukac
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janine T. Bryan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul F. Cavanaugh Jr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith S. Reisinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Abstract

OBJECTIVE. Prophylactic vaccination of 16- to 23-year-old females with a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to prevent type-specific human papillomavirus infection and associated clinical disease. We conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys, who represent a primary target for human papillomavirus vaccination.

METHODS. We enrolled 506 girls and 510 boys (10–15 years of age) and 513 females (16–23 years of age). Participants were vaccinated on day 1, at month 2, and at month 6, and serology testing was performed on day 1 and at months 3 and 7 on blinded samples. Neutralizing antibody concentrations were determined using type-specific immunoassays and summarized as geometric mean titers and seroconversion rates. Vaccine tolerability also was assessed.

RESULTS. By month 7, seroconversion rates were ≥99% for all 4 human papillomavirus types in each group. By month 7, compared with women, anti–human papilloma virus geometric mean titers in girls or boys were noninferior and were 1.7- to 2.7-fold higher. Most (>97%) injection-site adverse events were mild to moderate in intensity. Significantly more boys (13.8%) and girls (12.8%) than women (7.3%) reported fevers ≥37.8°C within 5 days of vaccination. Most (96.4%) fevers were mild (<39°C).

CONCLUSIONS. Noninferior immunogenic responses to all 4 human papillomavirus types in the quadrivalent vaccine permit the bridging of efficacy data that were generated in young women to girls. The results in boys lend support for the implementation of gender-neutral human papillomavirus vaccination programs. This vaccine generally was well tolerated.

  • HPV
  • vaccine
  • immunogenicity
  • reactogenicity
  • pediatric
  • noninferiority
  • Accepted July 28, 2006.
  • Copyright © 2006 by the American Academy of Pediatrics

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 118, Issue 5
November 2006
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women
Stan L. Block, Terry Nolan, Carlos Sattler, Eliav Barr, Katherine E.D. Giacoletti, Colin D. Marchant, Xavier Castellsagué, Steven A. Rusche, Suzanne Lukac, Janine T. Bryan, Paul F. Cavanaugh, Keith S. Reisinger
Pediatrics Nov 2006, 118 (5) 2135-2145; DOI: 10.1542/peds.2006-0461

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women
Stan L. Block, Terry Nolan, Carlos Sattler, Eliav Barr, Katherine E.D. Giacoletti, Colin D. Marchant, Xavier Castellsagué, Steven A. Rusche, Suzanne Lukac, Janine T. Bryan, Paul F. Cavanaugh, Keith S. Reisinger
Pediatrics Nov 2006, 118 (5) 2135-2145; DOI: 10.1542/peds.2006-0461
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Antibody binding to native cytomegalovirus glycoprotein B predicts vaccine efficacy
  • Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans
  • Ongoing inadequacy of quadrivalent HPV vaccine safety studies
  • Opportunistic HPV vaccination at age 16-23 and cervical screening attendance in Sweden: a national register-based cohort study
  • 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years
  • A Population-Based Study of Sociodemographic and Geographic Variation in HPV Vaccination
  • Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD
  • Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine
  • Immunogenicity and Safety of a 9-Valent HPV Vaccine
  • Skin and Mucosal Human Papillomavirus Seroprevalence in Persons with Fanconi Anemia
  • Human papillomavirus vaccination for boys
  • Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
  • Long-term Study of a Quadrivalent Human Papillomavirus Vaccine
  • Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study
  • "Time-Expanded" HPV Vaccine Schedules Provide Protection
  • Adherence to the HPV Vaccine Dosing Intervals and Factors Associated With Completion of 3 Doses
  • Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel
  • Should boys receive the human papillomavirus vaccine? Yes
  • Human papillomavirus prevalence and type distribution in penile carcinoma
  • Vaccination against human papillomavirus
  • Intention of parents to have male children vaccinated with the human papillomavirus vaccine
  • The Case for a Gender-Neutral (Universal) Human Papillomavirus Vaccination Policy in the United States: Point
  • Will vaccination against human papillomavirus prevent eye disease? A review of the evidence
  • Prophylactic HPV vaccines
  • Human papillomavirus vaccines launch a new era in cervical cancer prevention
  • How Effective Is the Quadrivalent HPV Vaccine at Preventing High-grade Cervical Lesions?
  • HPV Vaccine for Preadolescents and Adolescent Boys and Girls
  • Google Scholar

More in this TOC Section

  • Patterns and Predictors of Professional Interpreter Use in the Pediatric Emergency Department
  • Romantic Relationships in Transgender Adolescents: A Qualitative Study
  • Predictive Models of Neurodevelopmental Outcomes After Neonatal Hypoxic-Ischemic Encephalopathy
Show more Articles

Similar Articles

Subjects

  • Infectious Disease
    • Infectious Disease
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics